|May 8, 2019
||STELLA PHARMA CORPORATION has initiated consulting with PMDA for ‘SAKIGAKE Designation System’on SPM-011 after realizing achievement of their established goal on the clinical trial of Head & Neck cancer.
|April 21, 2017
||SPM-011 has been approved for prioritized review under the SAKIGAKE Designation System.
|February 28, 2017
||A leading-edge project we are collaboratively developing with Sumitomo Heavy Industries, the “Boron Neutron Capture Therapy (BNCT) System” has been approved for prioritized review under the SAKIGAKE Designation System.
|July 14, 2016
||“Notification of Commencement of Phase II Clinical Trials for Head and Neck Cancer Using Accelerator BNCT” issued.
|March 24, 2016
||“Concerning Third-Party Share Issuance” publicly released.